{
    "symbol": "ARDX",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-07 01:18:12",
    "content": " I think what's important to note is in these first 3 months, we've really hit some key parameters in terms of integrating into office prior authorization practices get -- they're having early favorable experience with prior authorization approval rates and they're having early favorable experience with the treatment of IBSRELA. We're finding that we have some nice redemption rate, so -- which really just makes IBSRELA affordable for patients with commercial payers, but we're also finding that patients who are Medicare patients or Medicaid patients, we're finding that they have affordable copays associated with their benefit plans."
}